1. Bigger, T.J., Schmidt, D.H., Kutt, H.: Relationship between the plasma level of diphenylhydantoin and its cardiac antiarrhythmic effects. Circulation38, 363?374 (1968).
2. Buchthal, F., Svensmark, O.: Aspects of the pharmacology of phenytoin (Dilantin) relevant to their dosage in the treatment of epilepsy. Epilepsia (Amster.)1, 374?384 (1960).
3. Burns, J.J.: Species differences and individual variations in drug metabolism. Metabolic factors controlling duration of drug action. Brodie, B.B. and Erdos, E. (Eds.). Oxford: Pergamon Press 1962.
4. Butler, T.C.: The metabolic conversion of 5-5-diphenylhydantoin to 5-(p-hydroxyphenyl)-5-phenalhydantoin. J. Pharmacol. exp. Ther.119, 1?11 (1957).
5. Collaborative group. Phenytoin after recovery from myocardial infarction. Lancet1971 II, 1055?1057.